Construction of a novel expression cassette for increasing transgene expression in vivo in endothelial cells of large blood vessels

Gene Therapy

Volumn 18, Issue 5, 2011, Pages 501-508

  Dronadula, N ^a   Du, L ^a   Flynn, R ^a   Buckler, J ^a   Kho, J ^a   Jiang, Z ^a   Tanaka, S ^a   Dichek, D A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

adenovirus; carotid artery; endothelium; gene expression regulation; interleukin 10

Indexed keywords

ADENOVIRUS VECTOR; ENDOTHELIN 1; INTERLEUKIN 10;

ANIMAL EXPERIMENT; AORTA; ARTICLE; CAROTID ARTERY; CELL SPECIFICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENDOTHELIUM CELL; ENHANCER REGION; GENE CASSETTE; GENE EXPRESSION REGULATION; MALE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY SEQUENCE; TRANSGENE; VASCULAR ENDOTHELIUM;

ADENOVIRIDAE; ANIMALS; CAROTID ARTERIES; CATTLE; CELL LINE; CYTOMEGALOVIRUS; DEFECTIVE VIRUSES; ENDOTHELIAL CELLS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERLEUKIN-10; MICE; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; RABBITS; REGULATORY SEQUENCES, NUCLEIC ACID; TRANSGENES;

ADENOVIRIDAE; BOVINAE; CYTOMEGALOVIRUS; EUKARYOTA; MURINAE; ORYCTOLAGUS CUNICULUS;

EID: 79955939666     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.173     Document Type: Article

References (45)

1. De Caterina R, Libby P (eds). Endothelial Dysfunctions and Vascular Disease. Blackwell: Malden, MA, 2007: 416 pp.
2. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355: 213-222. (Pubitemid 30068227)
3. Baker AH. Development and use of gene transfer for treatment of cardiovascular disease. J Card Surg 2002; 17: 543-548. (Pubitemid 36308371)
4. Gaffney MM, Hynes SO, Barry F, O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 2007; 152: 175-188. (Pubitemid 47517600)
5. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007; 15: 1233-1247. (Pubitemid 46965318)
6. Wen S, Schneider DB, Driscoll RM, Vassalli G, Sassani AB, Dichek DA. Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler Thromb Vasc Biol 2000; 20: 1452-1458. (Pubitemid 30353873)
7. Gruchala M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I et al. Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med 2004; 6: 545-554. (Pubitemid 40228070)
8. Channon KM, Qian H, Youngblood SA, Olmez E, Shetty GA, Neplioueva V et al. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. Circ Res 1998; 82: 1253-1262. (Pubitemid 28294744)
9. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96: 2955-2965.
10. Modlich U, Pugh CW, Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 2000; 7: 896-902. (Pubitemid 30303587)
11. Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG, Grizzle WE, Balyasnikova IV et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001; 19: 838-842. (Pubitemid 32816753)
12. Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 2001; 38: 65-70. (Pubitemid 34224772)
13. Velasco B, Ramirez JR, Relloso M, Li C, Kumar S, Lopez-Bote JP et al. Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters. Gene Therapy 2001; 8: 897-904. (Pubitemid 32600145)
14. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14: 1193-1206. (Pubitemid 36930408)
15. Richardson TB, Kaspers J, Porter CD. Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity. Gene Therapy 2004; 11: 775-783. (Pubitemid 38659756)
16. White SJ, Papadakis ED, Rogers CA, Johnson JL, Biessen EA, Newby AC. In vitro and in vivo analysis of expression cassettes designed for vascular gene transfer. Gene Therapy 2008; 15: 340-346. (Pubitemid 351267375)
17. Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Therapy 2001; 8: 819-827. (Pubitemid 32577186)
18. Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004; 113: 1017-1024. (Pubitemid 38544123)
19. Szymanski P, Anwer K, Sullivan SM. Development and characterization of a synthetic promoter for selective expression in proliferating endothelial cells. J Gene Med 2006; 8: 514-523.
20. Levanon K, Varda-Bloom N, Greenberger S, Barshack I, Goldberg I, Orenstein A et al. Vascular wall maturation and prolonged angiogenic effect by endothelial-specific platelet-derived growth factor expression. Pathobiology 2006; 73: 149-158. (Pubitemid 44699473)
21. Minami T, Aird WC. Endothelial cell gene regulation. Trends Cardiovasc Med 2005; 15: 174-184.
22. Papadakis ED, Nicklin SA, Baker AH, White SJ. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther 2004; 4: 89-113. (Pubitemid 38854948)
23. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004; 110: 1484-1491. (Pubitemid 39238028)
24. Bu X, Quertermous T. Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene. J Biol Chem 1997; 272: 32613-32622. (Pubitemid 28011951)
25. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892. (Pubitemid 29135675)
26. Terkeltaub RA. IL-10: an 'immunologic scalpel' for atherosclerosis? Arterioscler Thromb Vasc Biol 1999; 19: 2823-2825. (Pubitemid 30029805)
27. De Geest B, Van Linthout S, Lox M, Collen D, Holvoet P. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipo-protein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 2000; 11: 101-112. (Pubitemid 30044044)
28. Schneider DB, Vassalli G, Wen S, Driscoll RM, Sassani AB, DeYoung MB et al. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 2000; 20: 298-308. (Pubitemid 30086084)
29. Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, von Laer D et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Therapy 2006; 13: 641-645.
30. Schiedner G, Hertel S, Johnston M, Biermann V, Dries V, Kochanek S. Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol 2002; 76: 1600-1609. (Pubitemid 34094606)
31. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029. (Pubitemid 28072573)
32. Salem HK, Ranjzad P, Driessen A, Appleby CE, Heagerty AM, Kingston PA. Beta-adrenoceptor blockade markedly attenuates transgene expression from cytomegalovirus promoters within the cardiovascular system. Arterioscler Thromb Vasc Biol 2006; 26: 2267-2274. (Pubitemid 44465721)
33. Ross R. Atherosclerosis\an inflammatory disease. N Engl J Med 1999; 340: 115-126.
34. Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A et al. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol Ther 2008; 16: 1927-1936.
35. Shaw LC, Pan H, Afzal A, Calzi SL, Spoerri PE, Sullivan SM et al. Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovas-cularization. Gene Therapy 2006; 13: 752-760.
36. Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, Thompson AR et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 2000; 1: 522-532.
37. Xu ZL, Mizuguchi H, Ishii-Watabe A, Uchida E, Mayumi T, Hayakawa T. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 2001; 272: 149-156. (Pubitemid 32695407)
38. Dong G, Schulick AH, DeYoung MB, Dichek DA. Identification of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-b1 responsiveness in endothelium in vivo. J Biol Chem 1996; 271: 29969-29977. (Pubitemid 26389634)
39. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158. (Pubitemid 37272241)
40. Parks RJ, Bramson JL, Wan Y, Addison CL, Graham FL. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol 1999; 73: 8027-8034. (Pubitemid 29441662)
41. Houston P, White BP, Campbell CJ, Braddock M. Delivery and expression of fluid shear stress-inducible promoters to the vessel wall: applications for cardiovascular gene therapy. Hum Gene Ther 1999; 10: 3031-3044.
42. Perkins HD, van Leeuwen BH, Hardy CM, Kerr PJ. The complete cDNA sequences of IL-2, IL-4, IL-6 and IL-10 from the European rabbit (Oryctolagus cuniculus). Cytokine 2000; 12: 555-565. (Pubitemid 30453482)
43. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092. (Pubitemid 28215689)
44. Kingsman SM, Mitrophanous K, Olsen JC. Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Therapy 2005; 12: 3-4. (Pubitemid 40090038)
45. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509. (Pubitemid 26339054)